B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

53.89 -0.20 (-0.37%)
Delayed Quote Updated: 10:49 AM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
38 39 Next >
News headline image
Obesity-Drugs Focused Stocks Tumble On Wednesday - What's Going On With Eli Lilly, Novo Nordisk, Viking Therapeutics, Structure Therapeutics? ↗
Eli Lilly, Novo Nordisk, Viking Therapeutics, and Structure Therapeutics shares are down following Roche's promising CT-996 trial results for type 2 diabetes and obesity. Get insights into the latest... 
Via Benzinga
News headline image
Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study ↗
Roche reported promising topline results from a Phase 1 trial of CT-996, an oral GLP-1 receptor agonist for type 2 diabetes and obesity. Participants experienced a mean weight loss of 6.1% in four... 
Via Benzinga
News headline image
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity
From Genentech
Via Business Wire
News headline image
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)
From Genentech
Via Business Wire
News headline image
3 Small-Cap Stocks With Explosive 2X Growth Potential ↗
Discover three top high-growth small-cap stocks, fueled by potential rate cuts and promising prospects in the second half of 2024. 
Via InvestorPlace
News headline image
Roche's New Immunotherapy Fails To Show Benefit Over Merck's Blockbuster Keytruda In Lung Cancer Patients ↗
Roche's SKYSCRAPER-06 study of tiragolumab plus Tecentriq and chemotherapy did not meet primary endpoints for progression-free survival and overall survival in advanced non-squamous non-small cell lung... 
Via Benzinga
News headline image
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss
From Genentech
Via Business Wire
News headline image
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway ↗
The FDA has approved Epkinly as the first subcutaneously administered bispecific antibody for adults with relapsed or refractory follicular lymphoma after two or more lines of prior therapy. 
Via Benzinga
News headline image
Supreme Court Backs Pharmaceutical Giants in Iraq Terrorism Funding Case ↗
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism in Iraq, dismissing a lower court's ruling and sending the case back for... 
Via Benzinga
Topics Lawsuit
News headline image
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments ↗
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 30% on Giant FDA Boost ↗
How much Sarepta can hope to earn from Elevidys is unclear due to its cost, $3 million, and that it's not a cure. Yet SRPT stock is surging. 
Via InvestorPlace
News headline image
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
Via Benzinga
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors. 
Via MarketBeat
News headline image
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
News headline image
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
News headline image
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win ↗
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
News headline image
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
News headline image
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
News headline image
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk
From Genentech
Via Business Wire
News headline image
Italy Probes European Pharma Giants Novartis, Roche Over Eye Drug Competition Allegations ↗
Italy's antitrust authority is investigating Novartis and Roche's Genentech for allegedly delaying the Italian market launch of Byooviz, a Samsung Bioepis biosimilar of Lucentis. 
Via Benzinga
News headline image
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk ↗
You don't need to buy her picks, but it's worth understanding them. 
Via The Motley Fool
News headline image
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
From Genentech
Via Business Wire
News headline image
If You'd Invested $100 in Viking Therapeutics Stock 2 Years Ago, Here's How Much You'd Have Today ↗
What would a $100 investment in Viking Therapeutics back in 2022 be worth today? Prepare to be surprised. 
Via The Motley Fool
News headline image
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies ↗
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq. 
Via Benzinga
Topics Lawsuit
News headline image
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan ↗
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga
News headline image
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
From Genentech
Via Business Wire
News headline image
Roche To Ride Booming Obesity Treatment Market With Newly-Acquired Drug Candidate ↗
Roche's Genentech reported results from the Phase 1b trial of CT-388 for obesity and type 2 diabetes. The 24-week study showed significant weight loss and improved glycemic status in participants, with... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.